Irritable bowel syndrome remains a difficult condition to manage

Drug Benefit Trends

Volumn 16, Issue 6, 2004, Pages 313-322

  Talley, Nicholas J ^a,b  

^a Department of Medicine ^*  (United States)

^b Mayo Clinic   (United States)

Author keywords

GI disease; Irritable bowel syndrome; Randomized trials

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BULKING AGENT; CODEINE PHOSPHATE; COLESTYRAMINE; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; FLUOXETINE; HYOSCYAMINE; ISPAGULA; LOPERAMIDE; LORAZEPAM; MEBEVERINE; OPIATE AGONIST; PAROXETINE; POLYCARBOPHIL CALCIUM; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL TRIAL; CONSTIPATION; CORN; DIARRHEA; DIET THERAPY; DIETARY FIBER; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; LONG TERM CARE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; URINE RETENTION; VISUAL DISORDER; WHEAT BRAN;

EID: 3042597322     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360:555-564.
2. Drossman DA, Talley NJ, Corazziari ES, et al, eds. In: Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment - A Multinational Consensus. 2nd ed. McLean, Va: Degnon Associates; 2000.
3. Brandt L, Locke GR, Olden K, et al. An evidence-based approach to the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97:S1-S26.
4. Northcutt AR, Mangel AW, Hamm LR, et al. Persistent placebo response during a year-long controlled trial of IBS treatment. In: Program and abstracts of Digestive Disease Week 2001; May 20-23, 2001; Atlanta. Poster 3243.
5. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994;344:39-40.
6. Longstreth GE, Fox DD, Youkeles L, et al. Psyllium therapy in the irritable bowel syndrome: a double-blind trial. Ann Intern Med. 1981;95:53-56.
7. Arthurs Y, Fielding JF. Double blind trial of ispaghula/poloxamer in the irritable bowel syndrome. Ir Med J. 1983;76:253.
8. Arffmann S, Andersen JR, Hegnhoj J, et al. The effect of coarse wheat bran in the irritable bowel syndrome: a double-blind cross-over study. Scand J Gastroenterol. 1985;20:295-298.
9. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut. 1987; 28:1510-1513.
10. Lucey MR, Clark ML, Lowndes J, Dawson AM. Is bran efficacious in irritable bowel syndrome? A double blind, placebo controlled crossover study. Gut. 1987;28:221-225.
11. Cook IJ, Irvine EJ, Campbell D, et al. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome: a controlled, crossover study. Gastroenterology. 1990;98:66-72.
12. Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7:87-92.
13. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994;8:511-514.
14. Soltoft J, Krag B, Gudmand-Hoyer E, et al. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. Lancet. 1976;1:270-272.
15. Manning AP, Heaton KW, Harvey RF. Wheat fibre and irritable bowel syndrome: a controlled trial. Lancet. 1977;2:417-418.
16. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J. 1979;1:376-378.
17. Jalihal A, Kurian G. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction. J Gastroenterol Hepatol. 1990;5:507-513.
18. Golechha AC, Chadda VS, Chadda S, et al. Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). J Assoc Physicians India. 1982; 30:353-355.
19. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19:245-251.
20. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15:355-361.
21. Wheatley D. Irritable colon syndrome treated with an anti-spasmodic drug. The Practitioner. 1976;217:276-280.
22. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3:153-156.
23. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 1984;29:239-247.
24. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130:81-84.
25. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31:463-468.
26. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77-80.
27. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics. 1978;19: 340-547.
28. Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med. 1981-82;11:45-57.
29. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with the irritable bowel syndrome: a double-blind study. Scand J Gastroenterol. 1982;17:871-875.
30. Myren J, Lovland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol. 1984;19:835-843.
31. Greenbaum DS, Mayle JE, Vanegeren LE, et al. Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci. 1987;32:257-266.
32. Vij JG, Jiloha RG, Kumar N, et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry. 1991;33: 243-246.
33. Jailwala J, Imperiale T, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133:136-147.
34. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108:65-72.
35. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31.
36. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303-317.
37. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double-blind, randomized, placebo controlled study. Clin Gastroenterol Hepatol. 2003;1:219-228.
38. Chitkara DK, Cremonini F, Talley NJ. Psychotherapy and paroxetine: cost effective for severe IBS, or a waste of resources. Gastroenterology. 2003;125:1554-1555.
39. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther. 2001;15:277-289.
40. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666.
41. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
42. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut. 2003;52:671-667.
43. Lin SR, for the Tegaserod Clinical Research Group. A randomized, double-blind, placebo-controlled, multicenters study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2003;42:88-90.
44. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2004;(1): CD003960.
45. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol. 2002;97:1176-1181.
46. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1701-1708.
47. Schoenfeld P. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials. Aliment Pharmacol Ther. 2004;19:263-269.
48. Talley NJ. Serotoninergic neuroenteric modulators. Lancet. 2001;358:2061-2068.
49. 3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1159.
50. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled study. Lancet. 2000;355:1035-1040.
51. Bardhan KD, Bodernar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2000;14:23-34.
52. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001,96:2662-2670.
53. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil. 2003;15:79-86.
54. Jones RH, Holtnann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13:1419-1427.
55. Olden K, DeGarmo RG, Jhingran P, et al, for the Lotronex Investigator Team. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2002;97:3139-3146.
56. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:455-459.
57. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother. 2003; 4:2089-2098.
58. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol. 2003; 56:362-369.